NAMS
NewAmsterdam Pharma Company N.V.
23.60$
+4.4%
vs. previous close
Closing price · As of: Sep 28, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| – | – | – | -86.3% | +223.4% | -50.6% | |
| – | – | +385.7% | -37.2% | +154.5% | -47.8% | |
| – | – | – | -86.3% | +223.4% | -50.7% | |
| – | +486.4% | +199.4% | +83.8% | -5.0% | -6.3% | |
| – | +180.2% | +315.0% | +92.9% | +87.2% | +50.9% | |
| – | +427.4% | +203.8% | +85.5% | +12.6% | +11.8% | |
| – | – | – | – | – | – | |
| – | +19.5% | -30.2% | +2,269.0% | -100.0% | – | |
| – | – | – | – | – | – | |
| – | -37.2% | +32,692.6% | -100.0% | -103.7% | – | |
| – | – | – | – | – | – | |
| – | – | – | – | – | – |
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.